Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

NEEDHAM, MA - Verastem, Inc. (NASDAQ:VSTM), a $247.5 million market cap biopharmaceutical company focused on developing and ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

Barclays PLC raised its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...